Dietary soy isoflavones could prevent the accumulation of hepatic lipid droplets and delay the progression of NAFLD due to the regulation of lipogenesis and lipolysis, suppression of hepatic PPARγ2, and promotion of fatty acid oxidation (43, 44). The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatotic liver disease.